Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 6, 2004, Pages 475-486

  Smith, N F ^a   Hayes, A ^a   Nutley, B P ^a   Raynaud, F I ^a   Workman, P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

17AAG; Cassette dosing; Geldanamycin analogues; Hsp90 molecular chaperone; Pharmacokinetics

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; NSC 255110; NSC 682300; NSC 683661; NSC 683663; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SCREENING; DRUG TISSUE LEVEL; FEMALE; GENE CASSETTE; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; LIVER MICROSOME; MATHEMATICAL COMPUTING; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TECHNIQUE;

ANIMALS; BENZOQUINONES; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HALF-LIFE; LACTAMS, MACROCYCLIC; MICE; MICROSOMES, LIVER; QUINONES; TISSUE DISTRIBUTION;

EID: 11144283269     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0853-7     Document Type: Article

References (28)

1. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303
2. Banerji U, O'Donnell A, Scurr M, Benson C, Brock C, Hanwell J, Stapleton S, Raynaud F, Simmons L, Turner A, Walton M, Workman P, Judson I (2002) A pharmacokinetically (PK)-pharmacodynamically (PD) driven phase I trial of the HSP90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG). Proc Am Assoc Cancer Res 43:1352
3. Banerji U, Judson I, Workman P (2003) The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets 3:385
4. Bayliss MK, Frick LW (1999) High-throughput pharmacokinetics: cassette dosing. Curr Opin Drug Discov Devel 2:20
5. Berman J, Halm K, Adkison K, Shaffer J (1997) Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem 40(6):827
6. Brunton VG, Steele G, Lewis AD, Workman P (1998) Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 41:417
7. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385
8. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 micel. Cancer Chemother Pharmacol 47:291
9. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7
10. Erlichman C, Toft D, Reid J (2001) A phase I trial of 17-allylamino-geldanamycin in patients with advanced cancer. Proc Am Assoc Cancer Res 42:4474
11. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003
12. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P (1999) DT-diaphorase expression and tumor cell sensitivity to 17-allylamino-17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940
13. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2:3
14. Munster PN, Tong W, Schwartz L, Larson S, Kenneson K, De La Cruz A, Rosen N, Scher H (2001) Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 20:327
15. Musser SM, Egorin MJ, Zuhowski EG, Hamburger DR, Parise RA, Covey JM, White KD, Eiseman JL (2003) Biliary excretion of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats. Cancer Chemother Pharmacol 52:139
16. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski JE (1997) Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507) toxicity in rats. Proc Am Assoc Cancer Res 38:308
17. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17:4829
18. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P (2004) Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted CDK2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 3:353
19. Sausville EA, Tomaszewski JE, Ivy P (2003) Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 3:385
20. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273
21. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A (2000) Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 17:1551
22. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305
23. White RE, Manitpisitkul P (2001) Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos 29:957
24. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324
25. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, Saif MW, Allegra C, Grochow L, Szabo E, Hamilton M, Monahan BP, Neckers L, Grem JL (2001) Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumours. Proc Am Soc Clin Oncol 20:325
26. Workman P (2003) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies and molecular chaperones. Cancer Chemother Pharmacol 52 [Suppl 1]:S45
27. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Ramond R, Stables J, Stephens T (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd edn). Br J Cancer 77:1
28. Yuan J (1993) Estimation of variance for AUC in animal studies. J Pharm Sci 82:761